Home / Healthcare / Medical Device / U.S. Nebulizer Market
U.S. Nebulizer Market Size, Share & COVID-19 Impact Analysis, By Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer), By Modality (Tabletop and Portable), By End-user (Hospitals, Clinics, and Homecare Settings), and Country Forecast, 2023-2030
Report Format: PDF | Published Date: Sep, 2023 | Report ID: FBI108428 | Status : PublishedThe U.S. nebulizer market size was worth USD 372.9 million in 2022 and is projected to grow at a CAGR of 4.6% during the forecast period.
Nebulizers deliver drugs in the form of mist to treat diseases, such as asthma, Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, and other respiratory diseases. The increasing prevalence of such respiratory diseases has increased the demand for effective treatment, fueling the U.S. nebulizer market growth. Moreover, many market players have emphasized new advanced device development to fuel its rising demand.
- For instance, as per the information published by the Asthma and Allergy Foundation of America, in 2020, around 40.7% of adults aged 18 and above had asthma in the past year.
After the outbreak of COVID-19, the demand for nebulizers increased to control the severity of respiratory diseases. This had a positive impact on the market growth in 2020.
LATEST TRENDS
Growing Market Players’ Focus on New Product Launches to Boost Market Growth
The prevalence of respiratory diseases has been growing significantly in the U.S. For instance, according to the American Lung Association, in 2020, 12.5 million adults in the U.S. suffered from chronic obstructive pulmonary disease (COPD). In order to control such a high prevalence of these respiratory, market players increased their focus on the commercialization of new advanced products with convenient usability.
- In July 2020, OMRON Healthcare Inc. launched NE C106, a cost-effective compressor nebulization device. This new device was affordable and compatible for patiemts of all age groups. The main aim behind this launch was to strengthen its foothold in the emerging market.
The increasing focus of market players in commercializing technologically advanced and efficient nebulization devices has been increasing the accessibility of these devices to patients.
DRIVING FACTORS
Growing Favorable Reimbursement Policies to Propel Market Growth
The rise in respiratory diseases, such as asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and others, has been increasing the demand for devices, such as nebulizing devices to deliver drugs to the body to treat these diseases. This, along with the rising geriatric population, is also one reason for the increasing demand for these devices in the U.S. Regulatory bodies in the U.S. offer reimbursement to offset the high expenses associated with the treatment. This resulted in the increasing demand for these devices in the market.
- For instance, according to the U.S. Centers for Medicare & Medicaid Services (CMS), Medicaid covers nebulizing devices under the Durable Medical Equipment (DME) benefit.
Such favorable benefits of government policies have fueled the adoption of these devices, thereby fueling market growth.
The prevalence of asthma increased by 4.4% from 2021, affecting around 26.0 million of the U.S. population in 2022.
RESTRAINING FACTORS
Limitations Associated with the Use of Nebulizers is Limiting the Market Growth
The increasing prevalence of respiratory diseases has been fueling the adoption of nebulizers. However, factors, such as the higher risk of infection transmission from unsterile chambers or tubing of these devices, especially during long-term use, and the amount of medicine lost during drug delivery restrict its recommendation by healthcare professionals.
- According to a study published by National Center for Biotechnology Information (NCBI) in 2021, it was observed that the risk of infection transmission is higher while using the nebulizer via aerosols that can travel over a long distance and infect other people.
Such limitations associated with using these devices limit the demand for these devices and subsequently restrict their market growth.
SEGMENTATION
By Type Analysis
Based on type, this market is fragmented into jet nebulizer, ultrasonic nebulizer, and mesh nebulizer.
The mesh nebulizer segment is expected to grow significantly during the forecast period. The segment's growth is attributed to the increasing efficiency of these devices for delivering controlled quantities of drugs compared to other devices.
- For instance, a research study published by Springer Nature in 2023 stated that mesh nebulizers are more efficient in drug delivery than other such devices, because of their high output rate and small residual volume.
By Modality Analysis
Based on modality, the market is segmented into tabletop and portable.
The tabletop segment dominated the U.S. market in 2022 and is expected to dominate the market during the forecast period. The growth is attributed to the increasing preference for tabletop devices in end-user settings, such as hospital settings and the increasing preference for devices at long-term care centers. Moreover, these devices come under the Durable Medical Equipment (DME) benefits and are eligible for reimbursement policies under Medicare. Therefore, such favorable government policies have also been fueling segmental growth.
By End-user Analysis
Based on end-user, the market is segmented into hospitals, clinics, and homecare settings.
The hospitals segment dominated the market in 2022. The rising burden of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), increasing hospital admissions of patients suffering from these diseases, and the increasing demand for tabletop devices in these settings are responsible for the segment’s dominance.
- For instance, according to the data published by NCBI in 2022, it was reported that around 15.0 million people are suffering from chronic obstructive pulmonary disease (COPD) in the U.S. Nearly 700,000 hospitalizations are recorded yearly due to the condition in the U.S.
KEY INDUSTRY PLAYERS
Market players, such as OMRON Healthcare, Inc., Koninklijke Philips N.V., and Allied Healthcare Products, Inc. accounted for a significant U.S. nebulizer market share in 2022. The strong emphasis of market players on new product launches is expected to boost their growth in the market.
- For instance, in October 2020, OMRON Healthcare, Inc. announced the launch of CompAir Compressor Nebulizer. These devices are compact in shape and are designed specifically for children. With this launch, the company aimed to expand its product portfolio for nebulization devices.
Other players in the market, such as Pari GmbH, GF HEALTH PRODUCTS, INC., Aerogen, and Trudell Medical International, have been focusing on mergers and collaboration to expand their product portfolio.
LIST OF KEY COMPANIES PROFILED:
- OMRON Healthcare, Inc. (Japan)
- Koninklijke Philips N.V. (Netherlands)
- PARI Respiratory Equipment, Inc. (U.S.)
- DeVilbiss Healthcare LLC (U.S.)
- GF HEALTH PRODUCTS, INC. (U.S.)
- Trudell Medical International (Canada)
- Allied Healthcare Products, Inc. (U.S.)
- Teleflex Medical, Inc. (U.S.)
KEY INDUSTRY DEVELOPMENTS:
- September 2021 – Trudell Medical International’s Monaghan Medical Corporation, a manufacturer and developer of respiratory devices, including the AeroEclipse II Nebulizer, received the 2021 Zenith award from the American Association for Respiratory Care (AARC).
- March 2021 – OMRON Healthcare, Inc. donated nebulizers to the Asthma and Allergy Foundation of America (AAFA) to support and deliver these devices to people with asthma.
- September 2020 – Feellife Health Inc. received U.S. FDA approval for its mesh nebulizers. This helped the company to commercialize its products in the U.S. market.
REPORT COVERAGE
The market report provides a detailed analysis of the market. It focuses on key aspects such as an overview of technological advancements, the prevalence of respiratory disorders in the U.S., and pricing analysis. Additionally, it includes an overview of the reimbursement scenario for nebulization devices, new product launches, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market over recent years.
Report Scope & Segmentation
ATTRIBUTE | DETAILS |
Study Period | 2019-2030 |
Base Year | 2022 |
Estimated Year | 2023 |
Forecast Period | 2023-2030 |
Historical Period | 2019-2021 |
Growth Rate | CAGR of 4.6% from 2023 to 2030 |
Unit | Value (USD Million) |
Segmentation | By Type
|
By Modality
| |
By End-user
|
Frequently Asked Questions
How much is the U.S. nebulizer market worth?
Fortune Business Insights says that the U.S. market was worth USD 372.9 million in 2022.
At what CAGR is the U.S. Nebulizer Market projected to grow during the forecast period (2023-2030)?
The market is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).
Which is the leading segment in the market by product type?
By type, the jet nebulizer segment account for a considerable proportion of the market.
Who are the top players in the market?
OMRON Healthcare, Inc., Koninklijke Philips N.V., and Allied Healthcare Products, Inc. are the top players in the market.
- USA
- 2022
- 2019-2021
- 70